Methamphetamine reduces LTP and increases baseline synaptic transmission in the CA1 region of mouse hippocampus

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Swant, Jarod ^a,b   Chirwa, Sanika ^a,b   Stanwood, Gregg ^b,c   Khoshbouei, Habibeh ^a,b  

^a MEHARRY MEDICAL COLLEGE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR; ETICLOPRIDE; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SEROTONIN RECEPTOR; 1 (2 METHOXYPHENYL) 4 (4 (2 PHTHALIMIDO)BUTYL)PIPERAZINE; 1-(2-METHOXYPHENYL)-4-(4-(2-PHTHALIMIDO)BUTYL)PIPERAZINE; BENZAZEPINE DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT; PIPERAZINE DERIVATIVE; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; BRAIN SLICE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EX VIVO STUDY; HIPPOCAMPUS; LONG TERM POTENTIATION; MOUSE; NONHUMAN; RECEPTOR BLOCKING; SYNAPTIC TRANSMISSION; ANIMAL; C57BL MOUSE; DOSE RESPONSE; DRUG EFFECT; IN VITRO STUDY; PHYSIOLOGY;

MUS;

ANIMALS; BENZAZEPINES; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; LONG-TERM POTENTIATION; METHAMPHETAMINE; MICE; MICE, INBRED C57BL; PIPERAZINES; SEROTONIN ANTAGONISTS; SYNAPTIC TRANSMISSION;

EID: 77956208024     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011382     Document Type: Article

References (92)

1. CDC (2005) Acute public health consequences of methamphetamine laboratories-16 states, January 2000-June 2004. MMWR Morb Mortal Wkly Rep 54: 356-359.
2. SAMHSA (2007) Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS) Highlights - - 2006 National Admissions to Substance Abuse Treatment Services. OAS Series #S-40, DHHS Publication No. (SMA) 08-4313, Rockville, MD, 2007.
3. Cruickshank CC, Dyer KR (2009) A review of the clinical pharmacology of methamphetamine. Addiction 104: 1085-1099.
4. Lan KC, Lin YF, Yu FC, Lin CS, Chu P (1998) Clinical manifestations and prognostic features of acute methamphetamine intoxication. J Formos Med Assoc 97: 528-533.
5. Brown PL, Wise RA, Kiyatkin EA (2003) Brain hyperthermia is induced by methamphetamine and exacerbated by social interaction. J Neurosci 23: 3924-3929.
6. Barr AM, Panenka WJ, MacEwan GW, Thornton AE, Lang DJ, et al. (2006) The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci 31: 301-313.
7. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, et al. (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158: 377-382.
8. Sulzer D, Sonders MS, Poulsen NW, Galli A (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75: 406-433.
9. Stephans SE, Yamamoto BK (1994) Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse 17: 203-209.
10. Kaiya H, Takeuchi K, Yoshida H, Kondo T, Sanpei F, et al. (1983) Effects of subchronic treatment of methamphetamine haloperidol on the rat brain levels of GABA, glutamate and aspartate. Folia Psychiatr Neurol Jpn 37: 107-113.
11. Nash JF, Yamamoto BK (1992) Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res 581: 237-243.
12. Cook CE, Jeffcoat AR, Hill JM, Pugh DE, Patetta PK, et al. (1993) Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab Dispos 21: 717-723.
13. Newton TF, De La Garza R 2nd, Fong T, Chiang N, Holmes TH, et al. (2005) A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline. Pharmacol Biochem Behav 82: 704-711.
14. Fowler JS, Volkow ND, Logan J, Alexoff D, Telang F, et al. (2008) Fast uptake and long-lasting binding of methamphetamine in the human brain: comparison with cocaine. Neuroimage 43: 756-763.
15. O'Neil ML, Kuczenski R, Segal DS, Cho AK, Lacan G, et al. (2006) Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge. Synapse 60: 465-473.
16. Segal DS, Kuczenski R, O'Neil ML, Melega WP, Cho AK (2005) Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization. Psychopharmacology (Berl) 180: 501-512.
17. Scatton B, Simon H, Le Moal M, Bischoff S (1980) Origin of dopaminergic innervation of the rat hippocampal formation. Neurosci Lett 18: 125-131.
18. Loy R, Koziell DA, Lindsey JD, Moore RY (1980) Noradrenergic innervation of the adult rat hippocampal formation. J Comp Neurol 189: 699-710.
19. Schober W, Fischer W (1991) The projection of the locus coeruleus and the mesencephalic raphe nuclei to the hippocampal region of the rat: a study with horseradish peroxidase. J Hirnforsch 32: 409-420.
20. Vorel SR, Liu X, Hayes RJ, Spector JA, Gardner EL (2001) Relapse to cocaine-seeking after hippocampal theta burst stimulation. Science 292: 1175-1178.
21. Ricoy UM, Martinez JL Jr (2009) Local hippocampal methamphetamine-induced reinforcement. Front Behav Neurosci 3: 47.
22. Chambers RA, Self DW (2002) Motivational responses to natural and drug rewards in rats with neonatal ventral hippocampal lesions: an animal model of dual diagnosis schizophrenia. Neuropsychopharmacology 27: 889-905.
23. Brady AM, McCallum SE, Glick SD, O'Donnell P (2008) Enhanced methamphetamine self-administration in a neurodevelopmental rat model of schizophrenia. Psychopharmacology (Berl) 200: 205-215.
24. Thompson AM, Swant J, Gosnell BA, Wagner JJ (2004) Modulation of long-term potentiation in the rat hippocampus following cocaine self-administration. Neuroscience 127: 177-185.
25. Rogers JL, See RE (2007) Selective inactivation of the ventral hippocampus attenuates cue-induced and cocaine-primed reinstatement of drug-seeking in rats. Neurobiol Learn Mem 87: 688-692.
26. Sun W, Rebec GV (2003) Lidocaine inactivation of ventral subiculum attenuates cocaine-seeking behavior in rats. J Neurosci 23: 10258-10264.
27. Cadet JL, Jayanthi S, Deng X (2005) Methamphetamine-induced neuronal apoptosis involves the activation of multiple death pathways. Review. Neurotox Res 8: 199-206.
28. Nestler EJ (2001) Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2: 119-128.
29. Kauer JA, Malenka RC (2007) Synaptic plasticity and addiction. Nat Rev Neurosci 8: 844-858.
30. Thompson AM, Gosnell BA, Wagner JJ (2002) Enhancement of long-term potentiation in the rat hippocampus following cocaine exposure. Neuropharmacology 42: 1039-1042.
31. Thompson AM, Swant J, Wagner JJ (2005) Cocaine-induced modulation of long-term potentiation in the CA1 region of rat hippocampus. Neuropharmacology 49: 185-194.
32. Guan X, Zhang R, Xu Y, Li S (2009) Cocaine withdrawal enhances long-term potentiation in rat hippocampus via changing the activity of corticotropin-releasing factor receptor subtype 2. Neuroscience 161: 665-670.
33. del Olmo N, Higuera-Matas A, Miguens M, Garcia-Lecumberri C, Borcel E, et al. (2006) Hippocampal synaptic plasticity and water maze learning in cocaine self-administered rats. Ann N Y Acad Sci 1074: 427-437.
34. del Olmo N, Miguens M, Higuera-Matas A, Torres I, Garcia-Lecumberri C, et al. (2006) Enhancement of hippocampal long-term potentiation induced by cocaine self-administration is maintained during the extinction of this behavior. Brain Res 1116: 120-126.
35. Smith DA, Browning M, Dunwiddie TV (1993) Cocaine inhibits hippocampal long-term potentiation. Brain Res 608: 259-265.
36. Nishioku T, Shimazoe T, Yamamoto Y, Nakanishi H, Watanabe S (1999) Expression of long-term potentiation of the striatum in methamphetamine-sensitized rats. Neurosci Lett 268: 81-84.
37. Onaivi ES, Ali SF, Chirwa SS, Zwiller J, Thiriet N, et al. (2002) Ibogaine signals addiction genes and methamphetamine alteration of long-term potentiation. Ann N Y Acad Sci 965: 28-46.
38. Bliss TV, Lomo T (1973) Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol 232: 331-356.
39. Andersen P (1977) Long-lasting facilitation of synaptic transmission. Ciba Found Symp 87-108.
40. Cooke SF, Bliss TV (2006) Plasticity in the human central nervous system. Brain 129: 1659-1673.
41. Kim SJ, Linden DJ (2007) Ubiquitous plasticity and memory storage. Neuron 56: 582-592.
42. Schwartzkroin PA, Wester K (1975) Long-lasting facilitation of a synaptic potential following tetanization in the in vitro hippocampal slice. Brain Res 89: 107-119.
43. Swant J, Chirwa S, Khoshbouei H (2009) The acute effects of methamphetamine on synaptic plasticity in the CA1 region of mouse hippocampus. Society For Neuroscience Meeting 554.20/ AA20.
44. Stanwood GD, Parlaman JP, Levitt P (2005) Anatomical abnormalities in dopaminoceptive regions of the cerebral cortex of dopamine D1 receptor mutant mice. J Comp Neurol 487: 270-282.
45. Zombeck JA, Gupta T, Rhodes JS (2009) Evaluation of a pharmacokinetic hypothesis for reduced locomotor stimulation from methamphetamine and cocaine in adolescent versus adult male C57BL/6J mice. Psychopharmacology (Berl) 201: 589-599.
46. Riviere GJ, Gentry WB, Owens SM (2000) Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. J Pharmacol Exp Ther 292: 1042-1047.
47. Navakkode S, Sajikumar S, Frey JU (2007) Synergistic requirements for the induction of dopaminergic D1/D5-receptor-mediated LTP in hippocampal slices of rat CA1 in vitro. Neuropharmacology 52: 1547-1554.
48. Collingridge GL, Kehl SJ, McLennan H (1983) Excitatory amino acids in synaptic transmission in the Schaffer collateral-commissural pathway of the rat hippocampus. J Physiol 334: 33-46.
49. Malenka RC (1991) Postsynaptic factors control the duration of synaptic enhancement in area CA1 of the hippocampus. Neuron 6: 53-60.
50. Nicoll RA, Malenka RC (1999) Expression mechanisms underlying NMDA receptor-dependent long-term potentiation. Ann N Y Acad Sci 868: 515-525.
51. Moriguchi S, Watanabe S, Kita H, Nakanishi H (2002) Enhancement of N-methyl- D-aspartate receptor-mediated excitatory postsynaptic potentials in the neostriatum after methamphetamine sensitization. An in vitro slice study. Exp Brain Res 144: 238-246.
52. Herron CE, Lester RA, Coan EJ, Collingridge GL (1985) Intracellular demonstration of an N-methyl-D-aspartate receptor mediated component of synaptic transmission in the rat hippocampus. Neurosci Lett 60: 19-23.
53. Swant J, Wagner JJ (2006) Dopamine transporter blockade increases LTP in the CA1 region of the rat hippocampus via activation of the D3 dopamine receptor. Learn Mem 13: 161-167.
54. Huang YY, Kandel ER (1995) D1/D5 receptor agonists induce a protein synthesis-dependent late potentiation in the CA1 region of the hippocampus. Proc Natl Acad Sci U S A 92: 2446-2450.
55. Mockett BG, Brooks WM, Tate WP, Abraham WC (2004) Dopamine D1/D5 receptor activation fails to initiate an activity-independent late-phase LTP in rat hippocampus. Brain Res 1021: 92-100.
56. Otmakhova NA, Lisman JE (1996) D1/D5 dopamine receptor activation increases the magnitude of early long-term potentiation at CA1 hippocampal synapses. J Neurosci 16: 7478-7486.
57. Stramiello M, Wagner JJ (2008) D1/5 receptor-mediated enhancement of LTP requires PKA, Src family kinases, and NR2B-containing NMDARs. Neuropharmacology 55: 871-877.
58. Williams S, Mmbaga N, Chirwa S (2006) Dopaminergic D1 receptor agonist SKF 38393 induces GAP-43 expression and long-term potentiation in hippocampus in vivo. Neurosci Lett 402: 46-50.
59. Frey U, Matthies H, Reymann KG (1991) The effect of dopaminergic D1 receptor blockade during tetanization on the expression of long-term potentiation in the rat CA1 region in vitro. Neurosci Lett 129: 111-114.
60. Chirwa S, Aduonum A, Pizarro J, Reasor J, Kawai Y, et al. (2005) Dopaminergic DA1 signaling couples growth-associated protein-43 and long-term potentiation in guinea pig hippocampus. Brain Res Bull 64: 433-440.
61. El-Ghundi M, George SR, Drago J, Fletcher PJ, Fan T, et al. (1998) Disruption of dopamine D1 receptor gene expression attenuates alcohol-seeking behavior. Eur J Pharmacol 353: 149-158.
62. Drago J, Gerfen CR, Lachowicz JE, Steiner H, Hollon TR, et al. (1994) Altered striatal function in a mutant mouse lacking D1A dopamine receptors. Proc Natl Acad Sci U S A 91: 12564-12568.
63. Hollon TR, Bek MJ, Lachowicz JE, Ariano MA, Mezey E, et al. (2002) Mice lacking D5 dopamine receptors have increased sympathetic tone and are hypertensive. J Neurosci 22: 10801-10810.
64. Montague DM, Striplin CD, Overcash JS, Drago J, Lawler CP, et al. (2001) Quantification of D1B(D5) receptors in dopamine D1A receptor-deficient mice. Synapse 39: 319-322.
65. Schmitz D, Empson RM, Heinemann U (1995) Serotonin reduces inhibition via 5-HT1A receptors in area CA1 of rat hippocampal slices in vitro. J Neurosci 15: 7217-7225.
66. Kojima T, Matsumoto M, Togashi H, Tachibana K, Kemmotsu O, et al. (2003) Fluvoxamine suppresses the long-term potentiation in the hippocampal CA1 field of anesthetized rats: an effect mediated via 5-HT1A receptors. Brain Res 959: 165-168.
67. Creager R, Dunwiddie T, Lynch G (1980) Paired-pulse and frequency facilitation in the CA1 region of the in vitro rat hippocampus. J Physiol 299: 409-424.
68. Foster TC, McNaughton BL (1991) Long-term enhancement of CA1 synaptic transmission is due to increased quantal size, not quantal content. Hippocampus 1: 79-91.
69. Zucker RS (1999) Calcium- and activity-dependent synaptic plasticity. Curr Opin Neurobiol 9: 305-313.
70. Schneggenburger R, Neher E (2000) Intracellular calcium dependence of transmitter release rates at a fast central synapse. Nature 406: 889-893.
71. Katz B, Miledi R (1967) The timing of calcium action during neuromuscular transmission. J Physiol 189: 535-544.
72. Eckert R, Tillotson D, Ridgway EB (1977) Voltage-dependent facilitation of Ca2+ entry in voltage-clamped, aequorin-injected molluscan neurons. Proc Natl Acad Sci U S A 74: 1748-1752.
73. Katz B, Miledi R (1968) The role of calcium in neuromuscular facilitation. J Physiol 195: 481-492.
74. Goodwin JS, Larson GA, Swant J, Sen N, Javitch JA, et al. (2009) Amphetamine and methamphetamine differentially affect dopamine transporters in vitro and in vivo. J Biol Chem 284: 2978-2989.
75. Schwartzkroin PA (1975) Characteristics of CA1 neurons recorded intracellularly in the hippocampal in vitro slice preparation. Brain Res 85: 423-436.
76. Schwartzkroin PA (1977) Further characteristics of hippocampal CA1 cells in vitro. Brain Res 128: 53-68.
77. Shtark MB, Stratievsky VI, Ratushnjak AS, Voskresenskaja LV, Karasev NP (1976) A comparative statistical study of hippocampal neuronal spontaneous spike activity in situ and in vitro. J Neurobiol 7: 551-566.
78. Nicola SM, Kombian SB, Malenka RC (1996) Psychostimulants depress excitatory synaptic transmission in the nucleus accumbens via presynaptic D1-like dopamine receptors. J Neurosci 16: 1591-1604.
79. Burn JH, Rand MJ (1958) The action of sympathomimetic amines in animals treated with reserpine. J Physiol 144: 314-336.
80. Cragg SJ, Rice ME (2004) DAncing past the DAT at a DA synapse. Trends Neurosci 27: 270-277.
81. Stringer JL, Greenfield LJ, Hackett JT, Guyenet PG (1983) Blockade of long-term potentiation by phencyclidine and sigma opiates in the hippocampus in vivo and in vitro. Brain Res 280: 127-138.
82. Kalueff AV, Ren-Patterson RF, Murphy DL (2007) The developing use of heterozygous mutant mouse models in brain monoamine transporter research. Trends Pharmacol Sci 28: 122-127.
83. Granado N, Ortiz O, Suarez LM, Martin ED, Cena V, et al. (2008) D1 but not D5 dopamine receptors are critical for LTP, spatial learning, and LTP-Induced arc and zif268 expression in the hippocampus. Cereb Cortex 18: 1-12.
84. Kimura T, Ishihara K, Ozawa K, Sasa M (2004) Augmentation of serotonin-induced inhibition of neuronal activity in the hippocampus following repeated treatment with methamphetamine. Ann N Y Acad Sci 1025: 242-247.
85. Pugliese AM, Passani MB, Corradetti R (1998) Effect of the selective 5-HT1A receptor antagonist WAY 100635 on the inhibition of e.p.s.ps produced by 5-HT in the CA1 region of rat hippocampal slices. Br J Pharmacol 124: 93-100.
86. Jahnsen H (1980) The action of 5-hydroxytryptamine on neuronal membranes and synaptic transmission in area CA1 of the hippocampus in vitro. Brain Res 197: 83-94.
87. Segal M (1980) The action of serotonin in the rat hippocampal slice preparation. J Physiol 303: 423-439.
88. Brien JF, Kitney JC, Peachey JE, Rogers BJ (1978) Methamphetamine-induced behavioural effects and brain concentrations of methamphetamine and its metabolite amphetamine in mice. Res Commun Chem Pathol Pharmacol 22: 313-328.
89. Melega WP, Williams AE, Schmitz DA, DiStefano EW, Cho AK (1995) Pharmacokinetic and pharmacodynamic analysis of the actions of D-amphetamine and D-methamphetamine on the dopamine terminal. J Pharmacol Exp Ther 274: 90-96.
90. Riviere GJ, Byrnes KA, Gentry WB, Owens SM (1999) Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. J Pharmacol Exp Ther 291: 1220-1226.
91. Cook CE, Jeffcoat AR, Sadler BM, Hill JM, Voyksner RD, et al. (1992) Pharmacokinetics of oral methamphetamine and effects of repeated daily dosing in humans. Drug Metab Dispos 20: 856-862.
92. Cho AK, Melega WP, Kuczenski R, Segal DS (2001) Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse 39: 161-166.